TOP HEADLINES

Featured Story

Who's worried about the drug-pricing debate? Regeneron's CEO, for one

Are C-level execs really listening to the brouhaha over drug prices? With new drugs still rolling out in the U.S. at big premiums, one might think not. But if Regeneron chief Leonard Schleifer is speaking for his colleagues, then the answer is yes.

Allergan sets date for special meeting but vows to keep fighting Valeant buyout

Put it on the calendar: Allergan has scheduled its special shareholder meeting--key to Valeant's takeover attempt--for Dec. 18. But that doesn't mean it won't continue to fight the very idea in court.

Black box warning for antidepressants spelled the death of litigation

There used to be a legal specialty built by plaintiff attorneys around filing lawsuits against antidepressant makers and then settling them. But the black box warning put on antidepressants in 2004 has turned out to be a shroud for the once lucrative legal business.

Study sounds alarm on sleep-aid ingredient zolpidem

Sleep aids have landed in the safety spotlight recently, with regulatory agencies lowering dosages on some meds to ease side effect worries. But overmedication has its own set of risks, and a new study says those resulted in a doubling of emergency department visits between 2005 and 2010.

PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments have multiplied in cases across the country, testing that Second Circuit decision in other regions.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

A novel biomarker could make it easier for physicians to diagnose rheumatoid arthritis early, thereby improving patients' prospects. The best results come when conventional antibody testing is combined with the new biomarker.

FiercePharma Manufacturing

The big deal in contract manufacturing these days is biologics. Patheon is among those investing in facilities to capture more of that business. Patheon parent DPx has agreed to buy Gallus BioPharmaceuticals, presenting Patheon with its first biologics plants in the U.S.